AACR 2022 | Radionuclide conjugates 225Ac-J591 and 177Lu-PSMA-I&T for mCRPC

Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medical College, New York, NY, discusses results of a preclinical and initial Phase I study to evaluate the combined targeting of prostate-specific membrane antigen (PSMA) with alpha-radiolabeled antibody 225Ac-J591, and beta-radiolabeled ligand 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer (mCRPC). Preclinical tests demonstrated a synergistic effect between alpha and beta-emitting therapies, with increased site retention and cytotoxic effect observed. The combination therapy has a good safety profile and has progressed to an ongoing Phase II (NCT04886986) study. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.